Is IRONWOOD PHARMACEUTICALS INC (IRWD) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 104.7% / 30% | 37.8% / 30% | 8.2% / 30% | 1.38% / 5% | ✗ NOT HALAL |
| DJIM | 104.7% / 33% | 37.8% / 33% | 8.2% / 33% | 1.38% / 5% | ✗ NOT HALAL |
| MSCI | 150.6% / 33% | 54.3% / 33% | 11.8% / 33% | 1.38% / 5% | ✗ NOT HALAL |
| S&P | 104.7% / 33% | 37.8% / 33% | 8.2% / 33% | 1.38% / 5% | ✗ NOT HALAL |
| FTSE | 150.6% / 33% | 54.3% / 33% | 11.8% / 50% | 1.38% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 67.9% | |
| Operating Margin | 13.7% | |
| Net Margin | 8.1% | |
| Return on Assets (ROA) | 19.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $127M |
| Free Cash Flow | $127M |
| Total Debt | $598M |
| Current Ratio | 1.1 |
| Total Assets | $397M |
Price & Trading
| Last Close | $3.15 |
| 50-Day MA | $4.09 |
| 200-Day MA | $2.42 |
| Avg Volume | 4.8M |
| Beta | 0.2 |
|
52-Week Range
$0.53
| |
About IRONWOOD PHARMACEUTICALS INC (IRWD)
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is IRONWOOD PHARMACEUTICALS INC (IRWD) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), IRONWOOD PHARMACEUTICALS INC is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is IRONWOOD PHARMACEUTICALS INC's debt ratio?
IRONWOOD PHARMACEUTICALS INC's debt ratio is 104.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 150.6%.
What are IRONWOOD PHARMACEUTICALS INC's key financial metrics?
IRONWOOD PHARMACEUTICALS INC has a market capitalization of $499M, trailing P/E ratio of 20.4, and revenue of $296M. The company maintains a gross margin of 67.9% and a net margin of 8.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.